NCT01991184

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia. In a dose-expansion part, GDC-0853 will be assessed in subsets of patients.

Conditions

• Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	GDC-0853	Multiple escalating doses

Timeline

• Start date: 2013-12-16
• Primary completion: 2022-03-08
• Completion: 2022-03-08
• First posted: 2013-11-25
• Last updated: 2022-06-21

Locations

10 sites across 2 countries: United States, Australia